Morgan Stanley assumed coverage of Zenas BioPharma (ZBIO) with an Overweight rating with a price target of $31, down from $35. Upcoming readouts in 4Q25 the first half of 2026 could demonstrate the potential of inhibiting B cells in autoimmune conditions while building out the pipeline-in-a-product potential of obexelima, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBIO:
- Innovative Approach and Upcoming Catalysts Drive Buy Rating for Zenas BioPharma
- Zenas BioPharma Announces Board Changes at Annual Meeting
- Zenas BioPharma to Present at Jefferies Conference
- Zenas BioPharma Reports Q1 2025 Financial Results
- Zenas BioPharma’s Promising Autoimmune Pipeline and Obexelimab’s Competitive Edge Drive Buy Rating